What does Apotheek Hooglatem do?

Apotheek Hooglatem is a pharmacy in Sint-Martens-Latem. Public Limited, started on 16 November 1982, 1 establishment.

What is the address of Apotheek Hooglatem?

The registered office of Apotheek Hooglatem is located at Keistraat 30, 9830 Sint-Martens-Latem.

Is Apotheek Hooglatem still active?

Yes. According to the CBE (31 October 2026) Apotheek Hooglatem is active, legal situation “Normale toestand”, started on 16 November 1982.

Is Apotheek Hooglatem registered on Peppol?

Yes, Apotheek Hooglatem is registered on the Peppol network with ID 0208:0423236437.

What is the enterprise number of Apotheek Hooglatem?

The enterprise number of Apotheek Hooglatem is BE0423236437.

When was Apotheek Hooglatem founded?

Apotheek Hooglatem was founded on 16 November 1982.

Who are the directors of Apotheek Hooglatem?

According to the 2025 annual accounts, the directors of Apotheek Hooglatem are: MOFAR INVEST BV.

Is Apotheek Hooglatem a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 16 November 1982; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did Apotheek Hooglatem make in 2025?

Apotheek Hooglatem posted a profit after taxes of € 182,820 in financial year 2025.

What is the revenue of Apotheek Hooglatem?

As a small company, Apotheek Hooglatem is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 345,719.

How much does an employee at Apotheek Hooglatem earn?

The average wage cost per full-time employee at Apotheek Hooglatem was € 82,700 in 2025: staff costs of € 124,123 for 1.5 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does Apotheek Hooglatem have?

According to the 2025 annual accounts, Apotheek Hooglatem has 1.5 full-time equivalents (FTE).

Apotheek Hooglatem (Public Limited) - Sint-Martens-Latem

Dossier Apotheek Hooglatem, printed on 31 October 2026 from databakkes.be/en/0423236437/apotheek-hooglatem. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

Apotheek Hooglatem from Sint-Martens-Latem, company number BE0423236437, closed financial year 2025 with a result of € 182,820 after tax. For that financial year Apotheek Hooglatem recorded a gross margin of € 345,719 and equity of € 288,180. Compared with financial year 2024, the result moved from € 195,681 to € 182,820. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on April 1, 2026.

What it is worth Growing

€ 288,180

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 182,820

▼ 7% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 203,159

▼ 7% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 182,000 paid out

100 % of the profit went to the shareholders, mostly to MOFAR INVEST (100 % of the shares). That is where the money ends up.

People and assets in 2025

Full-time equivalents

1.5

▼ 0.1 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 124,123

▲ 1% vs 2024

€ 82,700 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 3,971

▼ 57% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

€ 7,500

▼ 93% vs 2024

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 76,143

▼ 4% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 28,550

▲ 7% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 263,573 Gross margin 2022: € 263,573 First fiscal year in the series	€ 295,143 Gross margin 2023: € 295,143 ▲ 12% vs 2022 (€ 263,573) Favourable step	€ 357,762 Gross margin 2024: € 357,762 ▲ 21% vs 2023 (€ 295,143) Favourable step	€ 345,719 Gross margin 2025: € 345,719 ▼ 3% vs 2024 (€ 357,762) Unfavourable step	▼ 3%
Profit after taxes	€ 117,947 Profit after taxes 2022: € 117,947 First fiscal year in the series	€ 60,899 Profit after taxes 2023: € 60,899 ▼ 48% vs 2022 (€ 117,947) Unfavourable step	€ 195,681 Profit after taxes 2024: € 195,681 ▲ 221% vs 2023 (€ 60,899) Favourable step	€ 182,820 Profit after taxes 2025: € 182,820 ▼ 7% vs 2024 (€ 195,681) Unfavourable step	▼ 7%
Equity	€ 285,779 Equity 2022: € 285,779 First fiscal year in the series	€ 286,679 Equity 2023: € 286,679 Unchanged (€ 285,779) Favourable step	€ 287,360 Equity 2024: € 287,360 Unchanged (€ 286,679) Favourable step	€ 288,180 Equity 2025: € 288,180 Unchanged (€ 287,360) Favourable step
Total debts	€ 455,451 Total debts 2022: € 455,451 First fiscal year in the series	€ 476,195 Total debts 2023: € 476,195 ▲ 5% vs 2022 (€ 455,451) Unfavourable step	€ 490,891 Total debts 2024: € 490,891 ▲ 3% vs 2023 (€ 476,195) Unfavourable step	€ 415,142 Total debts 2025: € 415,142 ▼ 15% vs 2024 (€ 490,891) Favourable step	▼ 15%
Cash	€ 172,496 Cash 2022: € 172,496 First fiscal year in the series	€ 229,367 Cash 2023: € 229,367 ▲ 33% vs 2022 (€ 172,496) Favourable step	€ 218,132 Cash 2024: € 218,132 ▼ 5% vs 2023 (€ 229,367) Unfavourable step	€ 203,159 Cash 2025: € 203,159 ▼ 7% vs 2024 (€ 218,132) Unfavourable step	▼ 7%
Land & buildings	€ 154,786 Land & buildings 2022: € 154,786 First fiscal year in the series	€ 135,818 Land & buildings 2023: € 135,818 ▼ 12% vs 2022 (€ 154,786) Unchanged	€ 118,534 Land & buildings 2024: € 118,534 ▼ 13% vs 2023 (€ 135,818) Unchanged	€ 112,020 Land & buildings 2025: € 112,020 ▼ 5% vs 2024 (€ 118,534) Unchanged	▼ 5%
Retained profit	€ 223,279 Retained profit 2022: € 223,279 First fiscal year in the series	€ 224,179 Retained profit 2023: € 224,179 Unchanged (€ 223,279) Favourable step	€ 224,860 Retained profit 2024: € 224,860 Unchanged (€ 224,179) Favourable step	€ 225,680 Retained profit 2025: € 225,680 Unchanged (€ 224,860) Favourable step
Dividend	€ 115,000 Dividend 2022: € 115,000 First fiscal year in the series	€ 60,000 Dividend 2023: € 60,000 ▼ 48% vs 2022 (€ 115,000) Unchanged	€ 195,000 Dividend 2024: € 195,000 ▲ 225% vs 2023 (€ 60,000) Unchanged	€ 182,000 Dividend 2025: € 182,000 ▼ 7% vs 2024 (€ 195,000) Unchanged	▼ 7%
Bank debt	€ 157,368 Bank debt 2022: € 157,368 First fiscal year in the series	€ 135,928 Bank debt 2023: € 135,928 ▼ 14% vs 2022 (€ 157,368) Favourable step	€ 113,964 Bank debt 2024: € 113,964 ▼ 16% vs 2023 (€ 135,928) Favourable step	€ 7,500 Bank debt 2025: € 7,500 ▼ 93% vs 2024 (€ 113,964) Favourable step	▼ 93%
Balance sheet total	€ 741,231 Balance sheet total 2022: € 741,231 First fiscal year in the series	€ 762,874 Balance sheet total 2023: € 762,874 ▲ 3% vs 2022 (€ 741,231) Unchanged	€ 778,251 Balance sheet total 2024: € 778,251 ▲ 2% vs 2023 (€ 762,874) Unchanged	€ 703,322 Balance sheet total 2025: € 703,322 ▼ 10% vs 2024 (€ 778,251) Unchanged	▼ 10%
Employees (FTE)	0 Employees (FTE) 2022: 0 First fiscal year in the series	1.5 Employees (FTE) 2023: 1.5 Unchanged (0) Unchanged	1.6 Employees (FTE) 2024: 1.6 ▲ 0.1 vs 2023 (1.5) Unchanged	1.5 Employees (FTE) 2025: 1.5 ▼ 0.1 vs 2024 (1.6) Unchanged	▼ 0.1

Key figures of Apotheek Hooglatem, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Apotheek Hooglatem?

What happened at Apotheek Hooglatem in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Apr 1, 2026 New annual accounts for financial year 2025: profit of € 182,820 (▼ 7% vs 2024). Source: NBB ↗
Nov 16, 1982 New establishment in Sint-Martens-Latem. KBO
Nov 16, 1982 Start of the company according to the CBE. KBO

In short

From € 117,947 profit in 2022 to € 182,820 profit in 2025.

Paid € 4,809 in corporate taxes since 2022.

Best year ever: 2024, with € 195,681 profit.

On average € 230,500 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

MOFAR INVEST 99.9%

The stake of MOFAR INVEST comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

Apotheek Hooglatem

Behind Apotheek Hooglatem is MOFAR INVEST BV. The shares are held by MOFAR INVEST (99.9%).

Directors

According to the 2025 annual accounts

MOFAR INVEST BV

Director · represented by Katrien Moentjens

Shareholders

MOFAR INVEST

99.9%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Keistraat 30

9830 Sint-Martens-Latem

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0423.236.437

VAT number

BE 0423.236.437

Registered office

Keistraat 30, 9830 Sint-Martens-Latem

Names & denominations

Apotheek Hooglatem

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

16 November 1982

Peppol

Active · Active since 17 Mar 2025

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

View on CBE Public ↗ Annual accounts (NBB) ↗

Apotheek Hooglatem

Financials

What happened to Apotheek Hooglatem?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Details

Frequently asked questions